The small North Yorkshire community of bentham has emerged as an epicentre of human exposure to so-called forever chemicals after a new set of blood tests found alarmingly high concentrations of PFAS in residents and former factory workers. The testing follows earlier discovery of extreme groundwater contamination on land linked to a local firefighting-foam manufacturer, and it now shows a pattern of body burdens that public-health experts say demand urgent clinical attention.
Why this matters right now
The timing is acute because the scale of contamination extends from the environment into human bodies. Groundwater in the town was previously identified as the most heavily contaminated with per- and polyfluoroalkyl substances in the country, found on land belonging to a factory that legally produced PFAS-containing firefighting foam between 1976 and 2024. Blood testing, conducted as part of a documentary investigation, reveals that exposure has translated into concentrations in people that are orders of magnitude above risk thresholds used elsewhere.
Bentham blood results: the numbers and what they mean
Thirty-nine people underwent blood testing. Almost a quarter — 23% — had PFAS levels that place them in what has been described as the highest risk category. The single highest measured blood concentration reached 405 ng/ml in a former factory worker, dwarfing benchmarks used by other countries. The National Academies of Sciences, Engineering, and Medicine (Nasem) has stated that a sum of seven PFAS chemicals in blood above 2 ng/ml presents potential for adverse health effects; Nasem further advises that levels above 20 ng/ml indicate increased risk and that clinicians should consider more frequent, targeted health screenings.
By those comparisons, several people from bentham sit well above clinically relevant thresholds. One resident, 34-year-old Stephen Illston, recorded a level of 55 ng/ml and described a history of fertility problems that he now links to the exposure. The tests suggest a localised exposure event with lingering human health implications rather than a diffuse, background-level contamination.
Deep analysis: causes, implications and ripple effects
The proximate cause of the contamination is tied to long-term manufacturing of PFAS-containing firefighting foam at a nearby factory. PFAS are persistent in the environment and bioaccumulate, moving from contaminated groundwater and soil into people over time. The combination of exceptionally high environmental concentrations and direct occupational contact for former workers creates a pattern consistent with both environmental exposure and occupational uptake.
Implications are multifold: individuals with elevated blood burdens may face increased risks tied to reproductive health and certain cancers; communities may wrestle with long-term health monitoring and the social and economic consequences of a contaminated water supply; and health services will need to decide how to deploy screening and follow-up for affected people given the absence of domestic blood-level guidance.
Expert perspectives and what experts are urging
Dr David Megson, forensic environmental scientist and PFAS expert at Manchester Metropolitan University, carried out an analysis of the blood results and compared them to levels in a reference population in the United States. He said: “I was absolutely shocked when I saw the data. The levels were exceptionally high compared to a general [US] background population. Nearly everybody we tested was above average and two-thirds of them were in the top 5%. A third of them were higher than anything we’d ever expect to see in the background population. So that was really shocking, and quite staggering. “
Dr Shubhi Sharma of the environmental charity Chem Trust has also commented on the gravity of the findings, reinforcing that the human measurements align with serious environmental contamination at the site linked to firefighting-foam manufacture.
Public-health authorities face a dilemma: there are no domestic guidelines that define a safe blood concentration for PFAS, yet international benchmarks point to levels now exceeded by multiple residents. That gap leaves clinicians and local services with decisions about screening schedules, specialist referrals, and long-term monitoring in an area where exposure was extensive and prolonged.
The local factory, identified as the site where PFAS-containing foam was produced for decades, is central to any attribution of cause. The cumulative release of PFAS into groundwater created an exposure pathway that ultimately shows up in these blood measurements, reinforcing the link between industrial activity, environmental contamination, and community health.
The findings raise broader questions about how communities with legacy contamination are identified, monitored and supported, and how occupational exposures are tracked for workers at facilities with long-term chemical use.
As bentham confronts the immediate human consequences of environmental contamination, the wider policy and clinical community must decide how to translate these data into screening, care and prevention — and what responsibility rests with manufacturers, regulators and health services to address the fallout. How will communities and health systems respond when contamination moves from groundwater into people’s bloodstreams, and what will meaningful remediation and care look like in the years ahead?
